What is the administration form of Zulresso for postpartum depression?

Zulresso, known generically as brexanolone, is specifically administered as an intravenous infusion for the treatment of postpartum depression. This route of administration allows for controlled dosing and rapid delivery of the medication directly into the bloodstream, which is crucial for effectively managing the acute symptoms associated with postpartum depression. The intravenous formulation enables clinicians to monitor the patient closely during the administration, ensuring that any potential side effects can be addressed promptly.

This method is particularly effective because brexanolone acts on the central nervous system to enhance GABA activity, which can lead to a quicker relief of symptoms compared to other forms of administration, such as oral tablets or nasal sprays. Hence, the intravenous infusion is designed for a specific treatment regimen, usually given over a designated period, often with a supervised setting to maximize the safety and efficacy of the treatment.